Five-Year Cardiorenal Outcomes and Longitudinal Chronic Kidney Disease Screening in People with Type 2 Diabetes Managed by Endocrinologists: A Nationwide Retrospective Cohort Study
Authors:
- José Ignacio Martínez-MontoroJMJosé Ignacio Martínez-Montoro
- José Juan Aparicio-SánchezJAJosé Juan Aparicio-Sánchez
- Belén PimentelBPBelén Pimentel
- Mónica Juárez-CampoMJMónica Juárez-Campo
- Maria Luisa AlamilloMAMaria Luisa Alamillo
- Yesika DíazYDYesika Díaz
- José Carlos Fernández-GarcíaJFJosé Carlos Fernández-García
Open Access
- 21 August 2026
- journal article
- research article
- Published by MDPI AG in Medical Sciences
- Vol. 14 (4) , 506
Abstract
Background/Objectives: Type 2 diabetes (T2D) is a major risk factor for cardiovascular disease and chronic kidney disease (CKD), yet the extent of longitudinal CKD screening in routine clinical practice remains unclear. This study aimed to assess long-term cardiorenal outcomes and CKD screening practices in patients with T2D managed across primary care and endocrinology settings, evaluating the feasibility of risk stratification in real-world practice. Methods: We conducted a retrospective cohort study using anonymized data from the Telotrón database (2.2 million patients). Adults with T2D attended across primary and endocrinology care were followed from 1 January 2018 to 31 December 2022. Frequency of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) measurements, and cumulative proportion of kidney and cardiovascular events, hospitalizations, and mortality were assessed. Results: Among 13,600 individuals, 31.1% experienced a kidney event and 18.6% a cardiovascular event over 5 years. All-cause hospitalization occurred in 24.9% and 16.1% died. First occurrence of an abnormal eGFR or UACR measurement occurred in 37.0% of participants without baseline CKD, and 45.4% with baseline CKD showed progression. Annual monitoring was limited, with 39.1% and 16.6% undergoing at least one yearly assessment, and 2.9 and 1.5 mean number of measurements per patient for eGFR and UACR, respectively. Conclusions: Despite receiving endocrinology care, kidney disease progression and cardiovascular events remain a major concern in T2D, and yet suboptimal albuminuria and eGFR assessment limit early detection and risk stratification, thereby hindering risk-directed management.Keywords
Funding Information
- AstraZeneca
- Instituto de Salud Carlos III (CM22/00217)
- Instituto de Salud Carlos III (JR24/00006)
- Instituto de Salud Carlos III (INT24/00051)
This publication has 35 references indexed in Scilit:
- Screening, prevalence, and burden of chronic kidney disease in people with type 2 diabetes managed by endocrinologists: A nationwide cross-sectional studyDiabetes Research and Clinical Practice, 2025
- Chronic kidney disease prevalence and outcomes in patients with type 2 diabetes or prediabetes at high cardiovascular risk: results from the CINEMA programAmerican Journal of Preventive Cardiology, 2025
- Multidisciplinary Panel Consensus for the Management of Patients with Type 2 Diabetes: A Delphi StudyArchives of Medical Research, 2023
- Manifestation of Heart Failure and Chronic Kidney Disease are Associated with Increased Mortality Risk in Early Stages of Type 2 Diabetes Mellitus: Analysis of a Japanese Real-World Hospital Claims DatabaseDiabetes Therapy, 2022
- Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) StudyClinical Therapeutics, 2021
- Development of Risk Prediction Equations for Incident Chronic Kidney DiseaseJAMA, 2019
- The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON studyDiabetologia, 2019
- The Association of Chronic Kidney Disease and Microalbuminuria with Heart Failure with Preserved vs. Reduced Ejection FractionEuropean Journal of Heart Failure, 2017
- Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014JAMA, 2016
- Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyDiabetologia, 2010